Tanaz Kermani is a Rheumatology/Immunology physician affiliated with University of California, Los Angeles. OpenAlex indexes 129 publications with 5,357 citations (h-index 39).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2020 Santa Monica Blvd
Suite 540
Santa Monica, CA 904042023
Telephone
310-582-6350Registry record last updated 1 Nov 2012.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20231 payment
- ABBVIE INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34.9%Folate Analog Metabolic Inhibitor14.5%Methotrexate100%Part D≥44 patientsTNF inhibitor6.2%Enbrel Sureclick82%Humira(Cf)18%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
28.3%Corticosteroid22.7%Prednisone100%Part D≥74 patientsAminosalicylate3.1%Sulfasalazine Dr62%Sulfasalazine38%Part D<11 patients+ 2 more classes in this area
Antiparasitic
11.9%Antimalarial11.9%Hydroxychloroquine Sulfate100%Part D≥50 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
Annals of the Rheumatic Diseases
2023 - Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan
Kidney International Reports
2023 - Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica – a prospective cohort study
Therapeutic Advances in Musculoskeletal Disease
2023 - Recent advances in the treatment of giant cell arteritis
Best Practice & Research Clinical Rheumatology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”